AstraZeneca's Pulmicort Posts $65 Mil. In Nine-Month U.S. Sales
Executive Summary
AstraZeneca's dry powder inhaled asthma therapy Pulmicort Turbuhaler posted nine-month sales of $65 mil. in the U.S., suggesting that the impact of supply constraints imposed by FDA may be beginning to ease, CEO Tom McKillop reported during an Oct. 28 teleconference on third quarter financial results.
You may also be interested in...
AstraZeneca Nexium NDA Includes "On-Demand" Dosing
AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.
AstraZeneca Nexium NDA Includes "On-Demand" Dosing
AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.
Casodex Prostate Cancer Monotherapy Survival Is Similar To Castration - U.K.
Prostate cancer treatment with AstraZeneca's Casodex (bicalutamide) as monotherapy does not increase mortality risk compared to castration, U.K. labeling for the anti-androgen indicates. The Medicines Control Agency cleared the indication on June 17.